We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
We open a new week of stock trading on the last day of August — a month that saw multiple new all-time highs reached on the Nasdaq and S&P 500, with the Dow inching ever-closer to its 2020 breakeven point. In fact, this is shaping up to be the strongest month of August in more than 30 years.
This, amid the ongoing pandemic that continues to claim 1000 American lives per day, social tension and violence being stoked in various corners of the country, and a labor environment where we still see around a million new jobless claims filed per week.
Advancements in treatments for COVID-19 and an extremely accommodative Fed are the two reasons the market has considered itself justified in keeping equity prices elevated, and in some ways it’s hard to argue with this. After all, should a vaccine appear at or around the end of the year (and this morning, a new GlaxoSmithKline (GSK - Free Report) and Vir Biotech (VIR - Free Report) antibody drug has just entered phase 2/3 testing), or Abbott Labs’ (ABT - Free Report) new quick $5 antigen test bring about a true sense of normalcy, what leg would market bears have to stand on?
Fed policies appear to be carved in stone at this point, suggesting the cheap money and historic low interest rate environment recently enacted is not in danger of being second-guessed until inflation levels are provably well above 2% for an extended period. This necessarily makes risk-taking the place to be to garner meaningful investment returns, which in turn hurts those looking to coddle their savings accounts. Short-term, this means higher equity valuations; longer-term, who knows?
Although this will be a big week for economic data — from Manufacturing & Services to Construction Spending and Productivity revisions, culminating in the U.S. Employment Situation report by the end of the week — today sees nothing new on this front. Markets are modestly higher at this hour, perhaps looking for direction. Then again, the trading week prior to the long Labor Day weekend is typically one of low trading volume overall.
So, while we’ll have plenty of grist for the mill for investors this week — including the ongoing saga of TikTok, which reportedly may announce a new buyer soon — today looks more like a holding pattern until we see something definitive emerge going into the first month of autumn. Bottom line, however: if you “Sold in May and went away,” you’ve got a lot of catching up to do now that you “Remembered to return in September.”
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Big Week of Econ Data Starts on a Lull
Monday, August 31, 2020
We open a new week of stock trading on the last day of August — a month that saw multiple new all-time highs reached on the Nasdaq and S&P 500, with the Dow inching ever-closer to its 2020 breakeven point. In fact, this is shaping up to be the strongest month of August in more than 30 years.
This, amid the ongoing pandemic that continues to claim 1000 American lives per day, social tension and violence being stoked in various corners of the country, and a labor environment where we still see around a million new jobless claims filed per week.
Advancements in treatments for COVID-19 and an extremely accommodative Fed are the two reasons the market has considered itself justified in keeping equity prices elevated, and in some ways it’s hard to argue with this. After all, should a vaccine appear at or around the end of the year (and this morning, a new GlaxoSmithKline (GSK - Free Report) and Vir Biotech (VIR - Free Report) antibody drug has just entered phase 2/3 testing), or Abbott Labs’ (ABT - Free Report) new quick $5 antigen test bring about a true sense of normalcy, what leg would market bears have to stand on?
Fed policies appear to be carved in stone at this point, suggesting the cheap money and historic low interest rate environment recently enacted is not in danger of being second-guessed until inflation levels are provably well above 2% for an extended period. This necessarily makes risk-taking the place to be to garner meaningful investment returns, which in turn hurts those looking to coddle their savings accounts. Short-term, this means higher equity valuations; longer-term, who knows?
Although this will be a big week for economic data — from Manufacturing & Services to Construction Spending and Productivity revisions, culminating in the U.S. Employment Situation report by the end of the week — today sees nothing new on this front. Markets are modestly higher at this hour, perhaps looking for direction. Then again, the trading week prior to the long Labor Day weekend is typically one of low trading volume overall.
So, while we’ll have plenty of grist for the mill for investors this week — including the ongoing saga of TikTok, which reportedly may announce a new buyer soon — today looks more like a holding pattern until we see something definitive emerge going into the first month of autumn. Bottom line, however: if you “Sold in May and went away,” you’ve got a lot of catching up to do now that you “Remembered to return in September.”
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>